HIM
IBB icon

HawsGoodwin Investment Management’s iShares Biotechnology ETF IBB Stock Holding History

HawsGoodwin Investment Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$8K Hold
50
– – ﹤0.01% 104
2021
Q3 		$8K Buy
+50
New +$8.41K ﹤0.01% 106

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

HawsGoodwin Investment Management's IBB Position: Q4 2021 in Review

HawsGoodwin Investment Management held its iShares Biotechnology ETF (IBB) position steady in Q4 2021 at 50 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #104.

HawsGoodwin Investment Management first reported a position in IBB in Q3 2021 and has held it in 2 quarters since. 962 funds tracked by Wall St. Rank hold IBB as of Q4 2021.

  • HawsGoodwin Investment Management held 50 shares of iShares Biotechnology ETF worth $8K as of Q4 2021.
  • HawsGoodwin Investment Management left its iShares Biotechnology ETF share count unchanged in Q4 2021.
  • iShares Biotechnology ETF made up ﹤0.01% of HawsGoodwin Investment Management's portfolio in Q4 2021, its #104 holding.
  • HawsGoodwin Investment Management first reported a position in iShares Biotechnology ETF in Q3 2021 and has held it in 2 quarters since.
  • 962 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2021.

Based on HawsGoodwin Investment Management's 13F filing for Q4 2021, filed 9 Feb 2022.